YM BioSciences Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From YM BioSciences Inc.
Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.
Now more than ever, surgeons have the option to pick which robot they wish to use in surgery. Picking apart the reasons why reveals much similarity between the two surgical disciplines.
Newcomers to the market have increased the number of options available to both soft tissue and orthopedic surgeons when selecting a robot. Despite the two disciplines' differences, the factors considered by surgeons when picking a system are relatively similar.
- Other Names / Subsidiaries
- Cytopia Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.